Xinlin Yu

Ms. Xinlin Yu


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 March 2025 in Vaccines
Verified
Journal Article
Open access
PDF file
RCRan Cui
Ran Cui
ZLZhongxiang Luo
Zhongxiang Luo
XZXialin Zhang
Xialin Zhang
XYXinlin Yu
Xinlin Yu
GYGang Yuan
Gang Yuan
OJOu Jiang
Ou Jiang
Phosphoinositide 3-kinases (PI3Ks), members of the lipid kinase family, play a significant role in modulating immune cell functions, including activation, proliferation, and differentiation. Recent studies have identified the PI3K signaling pathway as a key regulator in tumor biology and the immune microenvironment. This pathway enhances the activity of regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs), contributing to an immunosuppressive tumor microenvironment that impairs the effectiveness of cancer vaccines and immunotherapies. The present study explores PI3K isoforms, particularly p110γ and p110δ, and their associated signaling pathways. The therapeutic potential of selective PI3K inhibitors and their capacity to act synergistically with immunization strategies are analyzed. Targeting the PI3K signaling pathway represents a promising approach to counteract tumor-induced immune suppression and improve the efficacy of immune checkpoint inhibitors and vaccines, ultimately leading to better clinical outcomes.

1 January 2025 in International Journal of Clinical and Experimental Pathology
Verified
Journal Article
Closed access
HZHaifeng Zan
Haifeng Zan
MXMin Xu
Min Xu
PGPing Guo
Ping Guo
XYXinlin Yu
Xinlin Yu
Background: Afatinib, Dacomitinib, Osimertinib, Aumolertinib, Furmonertinib, Gefitinib, Erlotinib, and Icotinib have all been shown to work and be safe for people with epidermal growth factor receptor (EGFR)-positive non-small cell lung cancer (NSCLC) in recent years, but differences in efficacy, safety, and lack of comparative trials cause clinical confusion in treatment selection. This study analyzes their efficacy and safety via network meta-analysis to inform clinical decisions. Method: We searched PubMed, Embase, Cochrane Library, and Web of Science for pertinent studies. The objective response rate (ORR), median progression-free survival (mPFS), time to treatment failure (TTF), median overall survival (mOS), and adverse events (AEs) were then extracted. Result: In the efficacy analysis, Afatinib had the greatest ORR at SUCRA=95.9%, outperforming Gefitinib (SUCRA=22.7%) and Icotinib (SUCRA=30.7%). Furmonertinib had the longest mPFS of SUCRA=92.6%, outperforming Gefitinib (SUCRA=10.1%) and Afatinib (SUCRA=11.8%). Dacomitinib had the best TTF (SUCRA=84.1%), followed by Afatinib and Icotinib, which had a longer TTF than Gefitinib (SUCRA=7.0%). In safety evaluations, Aumolertinib performed best in overall grade 1-5 AEs (SUCRA=30.0%) and high-grade (≥3) AEs safety (SUCRA=9.5%), while Afatinib had the worst overall safety rating (SUCRA=68.3%), and Osimertinib had the worst high-grade (≥3) AEs profile. Afatinib and Osimertinib showed significantly greater grade ≥3 AEs compared to Furmonertinib, Icotinib, and Gefitinib. Aumolertinib had reduced frequencies of rash and diarrhea, while Afatinib/Dacomitinib had increased risks of vomiting. Conclusion: This network meta-analysis reveals that in first-line treatment, the third-generation EGFR-TKI Furmonertinib has exceptional advantages in mPFS and safety and is suited for patients with long-term disease control needs. Although second-generation Afatinib has the highest objective remission rate, it also increases the possibility of grade ≥3 AEs. Clinically, personalized programs should be devised based on the patient’s mutation type, tolerance, and other factors. More head-to-head trials will be required in the future to validate the findings and optimize treatment techniques.

15 March 2025 in Journal of Cardiovascular Pharmacology
Verified
Journal Article
Open access
PGPing Guo
Ping Guo
XYXinlin Yu
Xinlin Yu
MXMin Xu
Min Xu
YLYan Liu
Yan Liu
JJJie Jiang
Jie Jiang
Background: The therapeutic effects of different combination therapies containing cholesteryl ester transfer protein (CETP) inhibitors vary. Evidence from head-to-head comparisons is scarce and inconsistent. This study aimed to evaluate the impact of CETP inhibitor-based combination therapy on lipid levels and explore its adverse events (AEs). Method: Randomized controlled trials (RCTs) were retrieved from PubMed, Embase, Cochrane Library, and Web of Science up to August 30, 2025. Thirteen RCTs were analyzed through STATA 14.0. Results: This systematic review and network meta-analysis of 13 studies (9248 participants) evaluated CETP inhibitor-based combination therapies. For HDL-C elevation, obicetrapib + ezetimibe + statin ranked highest (SUCRA = 95.1%). Evacetrapib + statin achieved reduction in LDL-C (SUCRA = 94.3%). Obicetrapib + ezetimibe + statin excelled in reducing TC (SUCRA = 100.0%) and TG (SUCRA = 99.9%). Obicetrapib + statin was most effective for ApoAI increase (SUCRA = 100.0%), while obicetrapib + ezetimibe + statin best reduced ApoB (SUCRA = 100.0%). Regarding safety, obicetrapib + statin had the optimal profile for all grade AEs (SUCRA = 19.2%) and severe AEs (SUCRA = 22.5%), conversely, evacetrapib + statin had the worst profile (SUCRA = 83.1% and 66.3%, respectively). Conclusions: Our meta-analysis demonstrated that CETP inhibitor combination therapies offer distinct lipid-modulating benefits and safety profiles. The obicetrapib + ezetimibe + statin triple therapy showed superior comprehensive efficacy, while obicetrapib + statin exhibited the optimal safety. Evacetrapib + statin provided potent LDL-C reduction but had the poorest safety. These findings facilitate personalized treatment selection for dyslipidemia management. Trial registration: PROSPERO CRD420251145396 (https://www.crd.york.ac.uk/prospero/).